A detailed history of Virtus ETF Advisers LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 3,031 shares of ARWR stock, worth $77,502. This represents 0.05% of its overall portfolio holdings.

Number of Shares
3,031
Previous 3,243 6.54%
Holding current value
$77,502
Previous $99,000 13.13%
% of portfolio
0.05%
Previous 0.06%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$27.21 - $39.48 $5,768 - $8,369
-212 Reduced 6.54%
3,031 $86,000
Q4 2023

Feb 15, 2024

BUY
$21.2 - $31.03 $9,412 - $13,777
444 Added 15.86%
3,243 $99,000
Q3 2023

Nov 07, 2023

SELL
$26.2 - $36.08 $7,283 - $10,030
-278 Reduced 9.03%
2,799 $75,000
Q2 2023

Aug 14, 2023

SELL
$25.16 - $41.38 $25 - $41
-1 Reduced 0.03%
3,077 $109,000
Q1 2023

May 15, 2023

SELL
$23.68 - $38.51 $28,084 - $45,672
-1,186 Reduced 27.81%
3,078 $78,000
Q4 2022

Feb 14, 2023

BUY
$28.0 - $40.56 $14,616 - $21,172
522 Added 13.95%
4,264 $172,000
Q3 2022

Nov 14, 2022

BUY
$29.63 - $48.31 $711 - $1,159
24 Added 0.65%
3,742 $124,000
Q2 2022

Aug 12, 2022

BUY
$27.79 - $50.61 $40,573 - $73,890
1,460 Added 64.66%
3,718 $131,000
Q1 2022

May 16, 2022

SELL
$39.62 - $69.97 $5,626 - $9,935
-142 Reduced 5.92%
2,258 $104,000
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $174 - $247
-3 Reduced 0.12%
2,400 $159,000
Q3 2021

Nov 15, 2021

SELL
$58.38 - $84.96 $7,414 - $10,789
-127 Reduced 5.02%
2,403 $150,000
Q2 2021

Aug 10, 2021

SELL
$62.15 - $90.32 $91,733 - $133,312
-1,476 Reduced 36.84%
2,530 $210,000
Q1 2021

May 17, 2021

BUY
$61.35 - $90.47 $4,171 - $6,151
68 Added 1.73%
4,006 $266,000
Q4 2020

Feb 12, 2021

SELL
$43.82 - $85.37 $240,396 - $468,339
-5,486 Reduced 58.21%
3,938 $302,000
Q3 2020

Nov 13, 2020

SELL
$33.21 - $51.27 $42,542 - $65,676
-1,281 Reduced 11.97%
9,424 $406,000
Q2 2020

Aug 05, 2020

BUY
$26.12 - $43.27 $138,540 - $229,504
5,304 Added 98.2%
10,705 $462,000
Q1 2020

May 14, 2020

SELL
$20.56 - $63.12 $16,345 - $50,180
-795 Reduced 12.83%
5,401 $155,000
Q4 2019

Feb 13, 2020

SELL
$28.14 - $73.01 $100,994 - $262,032
-3,589 Reduced 36.68%
6,196 $393,000
Q3 2019

Nov 12, 2019

SELL
$26.26 - $34.86 $14,311 - $18,998
-545 Reduced 5.28%
9,785 $276,000
Q2 2019

Aug 13, 2019

SELL
$17.43 - $28.82 $135,779 - $224,507
-7,790 Reduced 42.99%
10,330 $274,000
Q1 2019

May 14, 2019

SELL
$12.05 - $20.18 $25,799 - $43,205
-2,141 Reduced 10.57%
18,120 $333,000
Q4 2018

Feb 05, 2019

SELL
$10.74 - $19.7 $207,120 - $379,914
-19,285 Reduced 48.77%
20,261 $252,000
Q3 2018

Nov 14, 2018

SELL
$14.0 - $20.3 $406,574 - $589,532
-29,041 Reduced 42.34%
39,546 $758,000
Q2 2018

Aug 10, 2018

BUY
$6.37 - $14.02 $436,899 - $961,589
68,587 New
68,587 $933,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.71B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.